Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial-Reference-Cited by-同舟云学术

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial

Published:2021-08 Issue: Volume:107 Page:106498
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Guerrieri-Gonzaga Aliana,Serrano Davide,Thomas Parjhitham,Crew Katherine D.,Kumar Nagi B.,Gandini Sara,Vornik Lana A.,Lee Jack,Cagnacci Sara,Vicini Elisa,Accornero Chiara A.,D'Amico Mauro,Guasone Flavio,Spinaci Stefano,Webber Tania B.,Brown Powel H.,Szabo Eva,Heckman-Stoddard Brandy,Bonanni Bernardo

Funder

Ministero della Salute

National Cancer Institute

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference29 articles.

1. Ki67 in breast cancer: prognostic and predictive potential;Yerushalmi;Lancet Oncol.,2010

2. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial;Decensi;Cancer Prev. Res. (Phila.),2011

3. Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial;Decensi;Cancer Prev. Res. (Phila.),2015

4. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women;Waters;Cancer Epidemiol. Biomark. Prev.,2010

5. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women;Decensi;J. Clin. Oncol.,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules;JNCI: Journal of the National Cancer Institute;2024-08-07

2. Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation;npj Breast Cancer;2024-01-18

3. Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs;JAMA Oncology;2023-05-01

4. Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer;JAMA Oncology;2023-05-01